Comparable stake leader
Coastlands Capital LP
SEC ownership of Pasithea Therapeutics Corp.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001841330.
Disclosed value leader
Vivo Opportunity Fund Holdings, L.P.
Comparable rows
31/50
Latest evidence
30 Jun 2026
- Public ticker
- KTTA, KTTAW on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Coastlands Capital LP
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
31 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Coastlands Capital LP
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001841330
- Issuer location
- Miami Beach, FL
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Pasithea Therapeutics Corp. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Coastlands Capital LP
Disclosed value leader
Vivo Opportunity Fund Hol...
Comparable rows
31/50
Latest evidence
30 Jun 2026
13D/G
3/4/5
13F
Lead comparable stake: 11%
19 rows are not safely comparable across share classes.
13D/G row: Coastlands Capital LP
Showing 1-8 of 50 holder rows.
Quick read
Coastlands Capital LP leads the comparable SEC ownership view at 11%.
31 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Coastlands Capital LP's linked filing trail.
Comparable ownership
Top 5
Coastlands Capital LP
11%
Vivo Opportunity Fund Holdings, L.P.
10%
Janus Henderson Group Ltd.
10%
Adage Capital Management, L.P.
10%
Squadron Capital Management LLC
9.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Coastlands Capital LP |
13D/G
3/4/5
10%+ Owner
|
11%
|
$2,339,371
3,835,035 shares
|
+$878,565 | 09 Apr 2026 |
| Vivo Opportunity Fund Holdings, L.P. |
13D/G
|
10%
|
$12,292,327
17,560,467 shares
|
$0 | 01 Dec 2025 |
| Janus Henderson Group Ltd. |
13D/G
13F
JANUS HENDERSON GROUP PLC · Company
|
10%
|
$7,160,756
10,229,652 shares
|
$0 | 28 Nov 2025 |
| Adage Capital Management, L.P. |
13D/G
|
10%
|
$2,050,179
2,329,749 shares
|
$0 | 31 Dec 2025 |
| Squadron Capital Management LLC |
13D/G
13F
Squadron Master Fund LP · Company
|
9.9%
|
$2,050,179
2,329,749 shares
|
+$67,601 | 31 Dec 2025 |
| Funicular Funds, LP |
13D/G
|
7.4%
|
$1,416,424
1,839,512 shares
|
$0 | 15 Apr 2026 |
| Opaleye Management Inc. |
13D/G
|
6.1%
|
$1,004,500
2,050,000 shares
|
-$216,090 | 30 Jun 2026 |
| Stonepine Capital Management, LLC |
13D/G
13F
Company
|
5.8%
|
$1,366,785
1,952,550 shares
|
$0 | 17 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$202,999.
Buys
$202,999
Insiders: 4
Sells
$0
Insiders: 0
Net
+$202,999
Shares: +299,999
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 299,999
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 100,000 | 0 | $53,000 | $0 | +$53,000 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 199,999 | 0 | $149,999 | $0 | +$149,999 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-19 of 19 reporting-owner rows connected to Pasithea Therapeutics Corp.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
19
Largest Forms 3/4/5 holder
Coastlands Capital LP
Net 12M change
+$203,000
Latest report
17 Jun 2026
Recent insider transactions for Pasithea Therapeutics Corp.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Coastlands Capital LP | KTTA | Common Stock | Purchase | 2.68% | $53,000 | $0.5300 | 100,000 | 3,835,035 | 17 Jun 2026 | By Coastlands Capital LP |
| Dr. Tiago Reis Marques | KTTA | Stock Option (right to buy) | Award | 1,756,069 | 1,756,069 | 01 May 2026 | Direct | |||
| Lawrence Steinman | KTTA | Stock Option (right to buy) | Award | 152,783 | 152,783 | 01 May 2026 | Direct | |||
| Simon Dumesnil | KTTA | Stock Option (right to buy) | Award | 152,783 | 152,783 | 01 May 2026 | Direct | |||
| Daniel H. Schneiderman | KTTA | Stock Option (right to buy) | Award | 1,129,323 | 1,129,323 | 01 May 2026 | Direct | |||
| Kartik Krishnan | KTTA | Stock Option (right to buy) | Award | 1,129,323 | 1,129,323 | 01 May 2026 | Direct | |||
| Dr. Emer Leahy | KTTA | Stock Option (right to buy) | Award | 152,783 | 152,783 | 01 May 2026 | Direct | |||
| Alfred J. Novak | KTTA | Stock Option (right to buy) | Award | 152,783 | 152,783 | 01 May 2026 | Direct | |||
| Lawrence Steinman | KTTA | Common Stock | Purchase | 200.9% | $100,000 | $0.7500 | 133,333 | 199,691 | 28 Nov 2025 | Direct |
| Daniel H. Schneiderman | KTTA | Common Stock | Award | 26,667 | 26,667 | 28 Nov 2025 | Direct | |||
| Dr. Tiago Reis Marques | KTTA | Common Stock | Purchase | 83.3% | $25,000 | $0.7500 | 33,333 | 73,334 | 28 Nov 2025 | Direct |
| Simon Dumesnil | KTTA | Common Stock | Purchase | 1333.3% | $25,000 | $0.7500 | 33,333 | 35,833 | 28 Nov 2025 | Direct |
| Dr. Emer Leahy | KTTA | Common Stock | Award | 33,333 | 33,333 | 28 Nov 2025 | Direct | |||
| Lawrence Steinman | KTTA | Stock Option (right to buy) | Award | 242,913 | 242,913 | 24 Oct 2025 | Direct | |||
| Daniel H. Schneiderman | KTTA | Stock Option (right to buy) | Award | 317,266 | 317,266 | 24 Oct 2025 | Direct | |||
| Alfred J. Novak | KTTA | Stock Option (right to buy) | Award | 42,913 | 42,913 | 24 Oct 2025 | Direct | |||
| Dr. Tiago Reis Marques | KTTA | Stock Option (right to buy) | Award | 493,341 | 493,341 | 24 Oct 2025 | Direct | |||
| Dr. Emer Leahy | KTTA | Stock Option (right to buy) | Award | 42,913 | 42,913 | 24 Oct 2025 | Direct | |||
| Simon Dumesnil | KTTA | Stock Option (right to buy) | Award | 42,913 | 42,913 | 24 Oct 2025 | Direct |
* marks a reported price that did not pass the local price check.